MCID: CLR109
MIFTS: 53

Colorectal Adenocarcinoma

Categories: Cancer diseases, Gastrointestinal diseases

Aliases & Classifications for Colorectal Adenocarcinoma

MalaCards integrated aliases for Colorectal Adenocarcinoma:

Name: Colorectal Adenocarcinoma 12 15
Adenocarcinoma of Large Intestine 73

Classifications:



External Ids:

Disease Ontology 12 DOID:0050861
UMLS 73 C1319315

Summaries for Colorectal Adenocarcinoma

Disease Ontology : 12 A colorectal carcinoma that derives from epithelial cells of glandular origin.

MalaCards based summary : Colorectal Adenocarcinoma, also known as adenocarcinoma of large intestine, is related to mucinous bronchioloalveolar adenocarcinoma and gastrointestinal stromal tumor. An important gene associated with Colorectal Adenocarcinoma is FABP6 (Fatty Acid Binding Protein 6), and among its related pathways/superpathways are Developmental Biology and fMLP Pathway. The drugs Iron and Ferric Compounds have been mentioned in the context of this disorder. Affiliated tissues include liver, colon and lung, and related phenotypes are Decreased viability and Decreased viability

Related Diseases for Colorectal Adenocarcinoma

Diseases related to Colorectal Adenocarcinoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 296)
# Related Disease Score Top Affiliating Genes
1 mucinous bronchioloalveolar adenocarcinoma 30.7 CDX2 KRT20 KRT7
2 gastrointestinal stromal tumor 30.4 BRAF EGFR KRAS TP53
3 villous adenoma 30.4 BRAF CDX2 KRAS KRT20
4 colorectal adenoma 30.2 CTNNB1 HRAS KRAS MLH1 MSH2 TP53
5 chordoma 30.1 CDH1 EGFR KRT7 TP53
6 adenocarcinoma 30.0 BRAF CDH1 CTNNB1 EGFR HRAS KRAS
7 suppression of tumorigenicity 12 29.7 BRAF CTNNB1 HRAS TP53
8 adenoma 29.2 BRAF CTNNB1 KRAS MLH1 MSH2 TP53
9 bladder adenocarcinoma 29.2 CDX2 CTNNB1 HRAS KRT20 KRT7
10 renal cell carcinoma, nonpapillary 28.8 CDH1 EGFR KRT20 KRT7
11 small intestinal adenocarcinoma 28.6 BRAF CDX2 CTNNB1 EGFR KRAS MUC2
12 squamous cell carcinoma 28.5 BRAF CDH1 CTNNB1 EGFR HRAS KRAS
13 mucinous adenocarcinoma 28.5 CDX2 EGFR KRAS KRT20 KRT7 MLH1
14 familial adenomatous polyposis 28.4 CDH1 CTNNB1 KRAS MLH1 MSH2 TP53
15 lynch syndrome 28.1 BRAF CTNNB1 KRAS MLH1 MSH2 MUC2
16 esophageal cancer 27.6 CDH1 CDX2 CEACAM5 CTNNB1 EGFR HRAS
17 hepatocellular carcinoma 27.6 CDH1 CEACAM5 CTNNB1 EGFR HRAS KRAS
18 lung cancer susceptibility 3 26.6 BRAF CDH1 CDX2 CEACAM5 CTNNB1 EGFR
19 gastric adenocarcinoma 25.2 BRAF CDH1 CDX2 CEACAM5 CTNNB1 EGFR
20 colorectal cancer 24.5 AURKA BRAF CDH1 CDX2 CEACAM5 CTNNB1
21 nevus of ota 11.0 BRAF TP53
22 rare adenocarcinoma of the breast 11.0 KRAS TP53
23 ovary neuroendocrine neoplasm 10.9 CDX2 KRT7
24 cystic basal cell carcinoma 10.9 KRT20 KRT7
25 hyperplastic polyposis syndrome 10.9 BRAF KRAS TP53
26 brain ependymoma 10.9 EGFR TP53
27 mature teratoma 10.9 BRAF KRAS TP53
28 mucoepidermoid esophageal carcinoma 10.9 CEACAM5 TP53
29 eccrine sweat gland neoplasm 10.9 KRT20 KRT7 TP53
30 seminal vesicle adenocarcinoma 10.9 KRT20 KRT7
31 transverse colon cancer 10.8 KRT20 KRT7
32 papillary serous adenocarcinoma 10.8 KRT20 KRT7 TP53
33 ovarian large-cell neuroendocrine carcinoma 10.8 KRT20 KRT7
34 glycogen-rich clear cell breast carcinoma 10.8 KRT20 KRT7 TP53
35 anal paget's disease 10.8 CDX2 CEACAM5
36 cutaneous mucoepidermoid carcinoma 10.8 CEACAM5 KRT7
37 anal gland adenocarcinoma 10.8 CEACAM5 KRT7
38 vaginal benign neoplasm 10.8 CDX2 KRT20 KRT7
39 appendix adenocarcinoma 10.8 CDX2 KRT20 KRT7
40 vaginal adenoma 10.8 CDX2 KRT20 KRT7
41 vaginal tubulovillous adenoma 10.8 CDX2 KRT20 KRT7
42 ovarian clear cell carcinoma 10.8 KRAS KRT7 TP53
43 glandular cystitis 10.8 CDX2 KRT20 KRT7
44 inverted papilloma 10.8 KRT20 KRT7 TP53
45 benign breast adenomyoepithelioma 10.8 EGFR KRT7
46 gallbladder squamous cell carcinoma 10.8 CEACAM5 TP53
47 jejunal adenocarcinoma 10.8 CDX2 KRT20 KRT7
48 sweat gland cancer 10.8 KRT20 KRT7 TP53
49 chronic cystitis 10.8 CDX2 KRT20 KRT7
50 eyelid neoplasm 10.8 KRT20 KRT7

Graphical network of the top 20 diseases related to Colorectal Adenocarcinoma:



Diseases related to Colorectal Adenocarcinoma

Symptoms & Phenotypes for Colorectal Adenocarcinoma

GenomeRNAi Phenotypes related to Colorectal Adenocarcinoma according to GeneCards Suite gene sharing:

26 (show all 16)
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased viability GR00055-A-2 10.92 KRAS EGFR HRAS PIM2 AURKA BRAF
2 Decreased viability GR00106-A-0 10.92 KRAS
3 Decreased viability GR00173-A 10.92 CDK8
4 Decreased viability GR00221-A-1 10.92 EGFR KRAS HRAS PIM2 CDH1 AURKA
5 Decreased viability GR00221-A-2 10.92 KRAS HRAS AURKA CDK8
6 Decreased viability GR00221-A-3 10.92 HRAS
7 Decreased viability GR00221-A-4 10.92 EGFR AURKA CDK8 BRAF
8 Decreased viability GR00231-A 10.92 AURKA
9 Decreased viability GR00301-A 10.92 KRAS MSH2 PIM2 CDH1 CDK8 BRAF
10 Decreased viability GR00381-A-1 10.92 KRAS BRAF
11 Decreased viability GR00402-S-2 10.92 EGFR KRAS HRAS MSH2 PIM2 AURKA
12 Decreased cell migration GR00055-A-1 9.97 HRAS PIM2 KRAS EGFR CDK8 BRAF
13 Decreased viability in esophageal squamous lineage GR00235-A 9.9 FABP6 KRAS KRT7 MLH1 HRAS TP53
14 Decreased cella89culturea89derived Hepatitis C virus (HCVcc; Luca89Jc1) infection GR00234-A-2 9.5 EGFR CDK8 BRAF
15 Increased cell migration GR00055-A-3 9.43 EGFR KRAS HRAS AURKA CTNNB1 BRAF
16 Increased cell viability after pRB stimulation GR00230-A-1 8.92 EGFR PIM2 AURKA CDK8

MGI Mouse Phenotypes related to Colorectal Adenocarcinoma:

46 (show all 11)
# Description MGI Source Accession Score Top Affiliating Genes
1 cellular MP:0005384 10.27 MSH2 MUC2 KRAS TP53 KRT7 MLH1
2 digestive/alimentary MP:0005381 10.22 HRAS MSH2 MUC2 KRAS TP53 MLH1
3 homeostasis/metabolism MP:0005376 10.22 HRAS MSH2 MUC2 KRAS TP53 KRT7
4 mortality/aging MP:0010768 10.17 HRAS MSH2 MUC2 KRAS TP53 MLH1
5 endocrine/exocrine gland MP:0005379 10.13 HRAS MUC2 KRAS TP53 MLH1 CTNNB1
6 embryo MP:0005380 10.11 KRAS TP53 CDX2 AURKA CTNNB1 BRAF
7 neoplasm MP:0002006 10.03 MSH2 MUC2 KRAS TP53 MLH1 HRAS
8 integument MP:0010771 10.02 HRAS MSH2 KRAS TP53 MLH1 CTNNB1
9 no phenotypic analysis MP:0003012 9.7 HRAS KRAS TP53 AURKA CTNNB1 CDH1
10 pigmentation MP:0001186 9.35 KRAS TP53 CTNNB1 BRAF EGFR
11 renal/urinary system MP:0005367 9.17 HRAS KRAS KRT7 TP53 CTNNB1 BRAF

Drugs & Therapeutics for Colorectal Adenocarcinoma

Drugs for Colorectal Adenocarcinoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 136)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Iron Approved Phase 4 7439-89-6 23925
2 Ferric Compounds Phase 4
3 Hematinics Phase 4,Phase 3,Phase 2,Phase 1
4 Hepcidins Phase 4
5 Iron Supplement Nutraceutical Phase 4
6
Bevacizumab Approved, Investigational Phase 3,Phase 2,Phase 1,Not Applicable 216974-75-3
7
Capecitabine Approved, Investigational Phase 3,Phase 2,Phase 1 154361-50-9 60953
8
Oxaliplatin Approved, Investigational Phase 3,Phase 2,Phase 1,Not Applicable 61825-94-3 5310940 9887054 43805 6857599
9
Fluorouracil Approved Phase 3,Phase 2,Phase 1,Not Applicable 51-21-8 3385
10
Levoleucovorin Approved, Investigational Phase 3,Phase 2,Phase 1 68538-85-2
11
Irinotecan Approved, Investigational Phase 2, Phase 3,Phase 1 97682-44-5, 100286-90-6 60838
12
Nicotine Approved Phase 3 54-11-5 942 89594
13
leucovorin Approved, Nutraceutical Phase 3,Phase 2,Phase 1,Not Applicable 58-05-9 143 6006
14
Folic Acid Approved, Nutraceutical, Vet_approved Phase 3,Phase 2,Phase 1,Not Applicable 59-30-3 6037
15
Glutamic Acid Approved, Nutraceutical Phase 3 56-86-0 33032
16 Angiogenesis Inhibitors Phase 3,Phase 2,Phase 1,Not Applicable
17 Angiogenesis Modulating Agents Phase 3,Phase 2,Phase 1,Not Applicable
18 Antimetabolites Phase 3,Phase 2,Phase 1,Not Applicable
19 Antimetabolites, Antineoplastic Phase 3,Phase 2,Phase 1,Not Applicable
20 Antidotes Phase 3,Phase 2,Phase 1,Not Applicable
21 Calcium, Dietary Phase 3,Phase 2
22 Immunosuppressive Agents Phase 3,Phase 2,Phase 1,Not Applicable
23 Protective Agents Phase 3,Phase 2,Phase 1,Not Applicable
24 Liver Extracts Phase 3,Phase 2,Phase 1,Not Applicable
25 Pharmaceutical Solutions Phase 3,Phase 2
26 Antibodies Phase 3,Phase 2,Phase 1
27 Antibodies, Monoclonal Phase 3,Phase 2,Phase 1
28 Immunoglobulins Phase 3,Phase 2,Phase 1
29 Micronutrients Phase 3,Phase 2,Phase 1,Not Applicable
30 Trace Elements Phase 3,Phase 2,Phase 1,Not Applicable
31 Vitamin B Complex Phase 3,Phase 2,Phase 1,Not Applicable
32 Vitamins Phase 3,Phase 2,Phase 1,Not Applicable
33 Bone Density Conservation Agents Phase 3,Phase 2
34 Endothelial Growth Factors Phase 3,Phase 2
35 Immunoglobulin G Phase 3,Phase 2
36 Mitogens Phase 3,Phase 2,Phase 1
37 Formyltetrahydrofolates Phase 3
38 Tetrahydrofolates Phase 3
39 Mitomycins Phase 2, Phase 3
40 Folate Nutraceutical Phase 3,Phase 2,Phase 1,Not Applicable
41 Vitamin B9 Nutraceutical Phase 3,Phase 2,Phase 1,Not Applicable
42
Paclitaxel Approved, Vet_approved Phase 2,Phase 1 33069-62-4 36314
43
Everolimus Approved Phase 2,Phase 1 159351-69-6 6442177
44
Miconazole Approved, Investigational, Vet_approved Phase 2,Phase 1 22916-47-8 4189
45
Sirolimus Approved, Investigational Phase 2,Phase 1 53123-88-9 5284616 6436030 46835353
46
Celecoxib Approved, Investigational Phase 2 169590-42-5 2662
47
Gefitinib Approved, Investigational Phase 2 184475-35-2 123631
48
Cetuximab Approved Phase 2,Phase 1 205923-56-4 56842117 2333
49
Tegafur Approved, Investigational Phase 2 17902-23-7 5386
50
Azacitidine Approved, Investigational Phase 1, Phase 2 320-67-2 9444

Interventional clinical trials:

(show top 50) (show all 119)
# Name Status NCT ID Phase Drugs
1 Intravenous Iron: Measuring Response in Anemic Surgical Patients Completed NCT02057471 Phase 4 Intravenous ferric carboxymaltose
2 IVICA: Intravenous Iron in Colorectal Cancer Associated Anaemia Completed NCT01701310 Phase 4 Ferric carboxymaltose;Ferrous Sulphate
3 Impact of Positron Emission Tomography Imaging Prior to Liver Resection for Colorectal Adenocarcinoma Metastases Completed NCT00265356 Phase 3
4 A Study of Avastin (Bevacizumab) and Xeloda (Capecitabine) as Maintenance Treatment in Patients With Metastatic Colorectal Cancer Completed NCT00623805 Phase 3 Bevacizumab;Capecitabine;Oxaliplatin
5 Study Comparing HAI Plus Chemotherapy and Chemotherapy Alone in Patients With Unresectable CRLM Recruiting NCT03125161 Phase 3 HAI;chemotherapy ± target therapy
6 Combination Chemotherapy, Bevacizumab, and/or Atezolizumab in Treating Patients With Deficient DNA Mismatch Repair Metastatic Colorectal Cancer Recruiting NCT02997228 Phase 3 Atezolizumab;Fluorouracil;Leucovorin Calcium;Oxaliplatin
7 5-FU Based Maintenance Therapy in RAS Wild Type Metastatic Colorectal Cancer After Induction With FOLFOX Plus Panitumumab Recruiting NCT03300609 Phase 3 Oxaliplatin;Leucovorin Calcium;Fluorouracil;Capecitabine
8 Perioperative Systemic Therapy and Surgery Versus Surgery Alone for Resectable Colorectal Peritoneal Metastases. Recruiting NCT02758951 Phase 2, Phase 3 Perioperative systemic therapy
9 A Study to Investigate Efficacy and Safety of Cobimetinib Plus Atezolizumab and Atezolizumab Monotherapy Versus Regorafenib in Participants With Metastatic Colorectal Adenocarcinoma (COTEZO IMblaze370) Active, not recruiting NCT02788279 Phase 3 Atezolizumab (MPDL3280A), an Engineered Anti-PDL1 Antibody;Cobimetinib;Regorafenib
10 Safety and Efficacy Study of Famitinib in Patients With Advanced Colorectal Adenocarcinoma(FACT) Active, not recruiting NCT02390947 Phase 3 Famitinib;Placebo
11 Efficacy and Safety Study of a Modified XELOX Regimen in First-Line Treatment of Metastatic Colorectal Adenocarcinoma Unknown status NCT01552967 Phase 2 Capecitabine
12 Phase II Study Evaluating the Efficacy and the Safety of Regorafenib in Patients Aged More Than 70 Years With a Metastatic Colorectal Adenocarcinoma . Unknown status NCT02788006 Phase 2 Regorafenib 160 mg
13 Efficacy/Safety Study of Bevacizumab,Capecitabine,Oxaliplatin to Metastatic Colorectal Adenocarcinoma Elderly Patients. Unknown status NCT01067053 Phase 2 bevacizumab, capecitabine, oxaliplatin
14 Neoadjuvant Radiation Therapy and Capecitabine in Treating Patients With Stage III or Stage IV Colorectal Adenocarcinoma Unknown status NCT00075556 Phase 2 capecitabine
15 Bevacizumab and Combination Chemotherapy in Treating Patients With Metastatic Colorectal Cancer Unknown status NCT00544011 Phase 2 capecitabine;fluorouracil;irinotecan hydrochloride
16 Capecitabine and Oxaliplatin in Treating Older Patients With Metastatic Colorectal Cancer Unknown status NCT00104689 Phase 2 capecitabine;oxaliplatin
17 Vaccine Therapy and Chemotherapy With or Without Tetanus Toxoid Compared With Chemotherapy Alone in Treating Patients With Metastatic Colorectal Cancer Unknown status NCT00027833 Phase 2 FOLFIRI regimen;fluorouracil;irinotecan hydrochloride;leucovorin calcium
18 Safety and Efficacy of S-8184 in Second Line Treatment of Stage III or IV Colorectal Adenocarcinoma Completed NCT00034190 Phase 2 S-8184 Paclitaxel Injectable Emulsion
19 Evaluation of Bevacizumab in Combination With First-Line Chemotherapy in Patients Aged 75 Years of Older With Metastatic Colorectal Adenocarcinoma (Prodige20) Completed NCT01900717 Phase 2 LV5FU2 simplified, FOLFOX 4 simplified, FOLFIRI modified;LV5FU2 simplified,FOLFOX 4 simplified, FOLFIRI modified, Bevacizumab 5 mg/kg/ 2 weeks
20 Study of 5-FU + Leucovorin + CPT-11 in Patients With Resectable Liver Metastases From Colorectal Adenocarcinoma Completed NCT00168155 Phase 2 perioperative chemotherapy
21 Study to Assess Safety and Tolerability of G17DT in Patients With Colorectal Adenocarcinoma. Completed NCT02181465 Phase 2
22 Phase II Trial of Lapatinib & Capecitabine for Patients With Refractory Advanced Colorectal Adenocarcinoma Completed NCT00574171 Phase 2 lapatinib;Capecitabine
23 Efficacy and Safety of Simtuzumab With FOLFIRI as Second Line Treatment in Colorectal Adenocarcinoma Completed NCT01479465 Phase 2 Simtuzumab;FOLFIRI;Placebo to match simtuzumab
24 DJ-927 as Second-Line Therapy in Treating Patients With Progressive Locally Advanced or Metastatic Colorectal Adenocarcinoma Completed NCT00080834 Phase 2 DJ-927
25 Efficacy and Safety of Everolimus in Patients With Metastatic Colorectal Cancer Who Have Failed Prior Targeted Therapy and Chemotherapy Completed NCT00419159 Phase 2 Everolimus (RAD001)
26 Expanded Cohort for Metastatic Colorectal Cancer (MCRC) Using Bevacizumab + Everolimus Completed NCT00597506 Phase 2 Bevacizumab;Everolimus
27 Capecitabine and Thalidomide in Previously Treated Metastatic Colorectal Carcinoma Completed NCT00165217 Phase 2 Capecitabine;Thalidomide
28 Abraxane in CIMP-High Colorectal and Small Bowel Adenocarcinomas Completed NCT01730586 Phase 2 Abraxane
29 Evaluation of Surgically Resected Colorectal Adenomas and Carcinomas After 7 Days Pretreatment With Celecoxib Completed NCT00582660 Phase 2 Celecoxib;Placebo
30 Bryostatin 1 in Treating Patients With Metastatic Colorectal Cancer Completed NCT00003220 Phase 2 bryostatin 1
31 Gefitinib in Treating Patients With Recurrent Metastatic Colorectal Cancer Completed NCT00025350 Phase 2 gefitinib
32 Study to Evaluate the Safety, Tolerability and Efficacy of FOLFOX + CT-011 Versus FOLFOX Alone Completed NCT00890305 Phase 2 CT-011;FOLFOX
33 Safety & Efficacy of NV1020 in Colorectal Cancer Metastatic to the Liver Completed NCT00149396 Phase 1, Phase 2 NV1020
34 1st Line Chemotherapy Alone or With Bevacizumab in Treating Older Patients With Metastatic Colorectal Cancer Completed NCT01417494 Phase 2 Chemotherapy ( FOLFIRI regimen, FOLFOX regimen or LV5FU2 regimen);Chemotherapy ( FOLFIRI regimen, FOLFOX regimen or LV5FU2 regimen) + bevacizumab
35 Tarceva, Capecitabine and Oxaliplatin for Metastatic Colorectal Cancer Completed NCT00123851 Phase 2 Tarceva (OSI-774);Capecitabine;Oxaliplatin
36 Erbitux Study of CPT11, Oxaliplatin, UFToral Targeted Therapy Completed NCT01225744 Phase 2 Cetuximab;Irinotecan;Oxaliplatin;UFT
37 Effect of TroVax in Patients Having Colorectal Cancer With Liver Metastases Removed Completed NCT00259844 Phase 2
38 Azacitidine and CAPOX in Metastatic Colorectal Cancer Completed NCT01193517 Phase 1, Phase 2 Azacitidine;Capecitabine;Oxaliplatin;Azacitidine MTD
39 Stereotactic Body Radiation Therapy (SBRT) for Unresectable Liver Metastases Recruiting NCT02185443 Phase 2
40 Study of Chemotherapy With or Without Hepatic Arterial Infusion for Patients With Unresectable Metastatic Colorectal Cancer to the Liver Recruiting NCT03069950 Phase 2 Floxuridine (FUDR);Irinotecan (CPT-11);FLUOROURACIL;PANITUMUMAB;DEXAMETHASONE;Leucovorin
41 Trial of Liver Resection Versus No Surgery in Patients With Liver and Unresectable Pulmonary Metastases From Colorectal Cancer (Liver Resection With Unresectable Lung Nodules From Colorectal Adenocarcinoma - LUNA) Recruiting NCT02738606 Phase 2 Chemotherapy
42 PhII Trial Panitumumab, Nivolumab, Ipilimumab in Kras/Nras/BRAF Wild-type MSS Refractory mCRC Recruiting NCT03442569 Phase 2 Panitumumab;Nivolumab;Ipilimumab
43 Open-Label Phase 2 Efficacy Trial of Cancer Macrobeads in Patients With Treatment-Resistant Pancreatic or Colorectal Cancer Recruiting NCT01053013 Phase 2
44 A Study to Evaluate Ibrutinib Combination Therapy in Patients With Selected Gastrointestinal and Genitourinary Tumors Recruiting NCT02599324 Phase 1, Phase 2 ibrutinib;everolimus;docetaxel;paclitaxel;cetuximab
45 Regorafenib in Metastatic Colorectal Cancer Recruiting NCT02466009 Phase 2 Regorafenib
46 Phase 2 Study of MK-3475 in Patients With Microsatellite Unstable (MSI) Tumors Recruiting NCT01876511 Phase 2 MK-3475;MK-3475
47 A Phase I/II Study of Pexa-Vec Oncolytic Virus in Combination With Immune Checkpoint Inhibition in Refractory Colorectal Cancer Recruiting NCT03206073 Phase 1, Phase 2
48 TAS102 in Combination With NAL-IRI in Advanced GI Cancers Recruiting NCT03368963 Phase 1, Phase 2 Nanoliposomal Irinotecan;Trifluridine and Tipiracil Hydrochloride
49 Tucatinib (ONT-380) and Trastuzumab in Treating Patients With HER2+ Metastatic Colorectal Cancer Recruiting NCT03043313 Phase 2 Tucatinib
50 Panitumumab in Combination With Trametinib in Cetuximab-Refractory Stage IV Colorectal Cancer Recruiting NCT03087071 Phase 2 Panitumumab;Trametinib

Search NIH Clinical Center for Colorectal Adenocarcinoma

Genetic Tests for Colorectal Adenocarcinoma

Anatomical Context for Colorectal Adenocarcinoma

MalaCards organs/tissues related to Colorectal Adenocarcinoma:

41
Liver, Colon, Lung, Endothelial, Bone, Kidney, Prostate

Publications for Colorectal Adenocarcinoma

Articles related to Colorectal Adenocarcinoma:

(show top 50) (show all 627)
# Title Authors Year
1
Histology of colorectal adenocarcinoma with double somatic mismatch repair mutations is indistinguishable from those caused by lynch syndrome. ( 29723603 )
2018
2
SCF/c-KIT Signaling Increased Mucin2 Production by Maintaining Atoh1 Expression in Mucinous Colorectal Adenocarcinoma. ( 29786668 )
2018
3
MAPK inhibitors induce serine peptidase inhibitor Kazal type 1 (SPINK1) secretion in BRAF V600E-mutant colorectal adenocarcinoma. ( 29193645 )
2018
4
Collision tumor consisting of a colorectal adenocarcinoma and dissemination of a gastric adenocarcinoma. ( 29326826 )
2018
5
Expression of Epidermal Growth Factor Receptor in Colorectal Adenocarcinoma and its Correlation with Clinicopathological Factors. ( 29950257 )
2018
6
In vivo identification of novel TGIF2LX target genes in colorectal adenocarcinoma using the cDNA-AFLP method. ( 29960902 )
2018
7
Cellular mechanism of resistance of human colorectal adenocarcinoma cells against apoptosis-induction by Russell's Viper venom l-amino acid oxidase (Rusvinoxidase). ( 29702182 )
2018
8
Hepatobiliary and Pancreatic: Hepatic nodules in a patient with familial adenomatous polyposis and colorectal adenocarcinoma. ( 29284077 )
2018
9
Localized lymphoid hyperplasia of the spleen mimicking metastatic colorectal adenocarcinoma. ( 29952067 )
2018
10
MET amplification, expression, and exon 14 mutations in colorectal adenocarcinoma. ( 29641976 )
2018
11
Predictors for local recurrence and distant metastasis of mucinous colorectal adenocarcinoma. ( 29361368 )
2018
12
Nuclear expression of claudin-3 in human colorectal adenocarcinoma cell lines and tissues. ( 29285188 )
2018
13
Lysine-specific demethylase 2A expression is associated with cell growth and cyclin D1 expression in colorectal adenocarcinoma. ( 29683067 )
2018
14
Expression of GAEC1 mRNA and protein and its association with clinical and pathological parameters of patients with colorectal adenocarcinoma. ( 29337242 )
2018
15
Validation of a targeted next-generation sequencing approach to detect mismatch repair deficiency in colorectal adenocarcinoma. ( 29955144 )
2018
16
Investigating the association between African spontaneously fermented dairy products, faecal carriage of Streptococcus infantarius subsp. infantarius and colorectal adenocarcinoma in Kenya. ( 29079186 )
2018
17
Triple primary malignancies in a patient with colorectal adenocarcinoma: A case report. ( 29216528 )
2018
18
Decreased Expression of the Polarity Regulatory PAR Complex Predicts Poor Prognosis of the Patients with Colorectal Adenocarcinoma. ( 29220829 )
2018
19
High microRNA-28-5p expression in colorectal adenocarcinoma predicts short-term relapse of node-negative patients and poor overall survival of patients with non-metastatic disease. ( 29688883 )
2018
20
Colorectal Adenocarcinoma with an Alternative Serrated Pathway. ( 29805354 )
2018
21
Expression and location of IL-17A, E, F and their receptors in colorectal adenocarcinoma: Comparison with benign intestinal disease. ( 29548809 )
2018
22
The Smad4/PTEN Expression Pattern Predicts Clinical Outcomes in Colorectal Adenocarcinoma. ( 29056035 )
2018
23
CT-based Radiomics Signature to Discriminate High-grade From Low-grade Colorectal Adenocarcinoma. ( 29503175 )
2018
24
Long Noncoding RNAs in Colorectal Adenocarcinoma; an in silico Analysis. ( 29948619 )
2018
25
Anatomical subsite can modify the association between meat and meat compounds and risk of colorectal adenocarcinoma: findings from three large US cohorts. ( 29873077 )
2018
26
p38 inhibitor inhibits the apoptosis of cowanin-treated human colorectal adenocarcinoma cells. ( 29620273 )
2018
27
Metformin and aspirin treatment could lead to an improved survival rate for Type 2 diabetic patients with stage II and III colorectal adenocarcinoma relative to non-diabetic patients. ( 29456855 )
2018
28
Ultrastructure of colorectal adenocarcinoma and peritumoral tissue in untreated patients. ( 29419351 )
2018
29
Intermittent low dose irradiation enhances the effectiveness of radio- and chemo-therapy for human colorectal adenocarcinoma cell line HT-29. ( 28560404 )
2017
30
miRNA biogenesis-associated RNase III nucleases Drosha and Dicer are upregulated in colorectal adenocarcinoma. ( 28943952 )
2017
31
Expression of pattern recognition receptor genes and mortality in patients with colorectal adenocarcinoma. ( 28533893 )
2017
32
Clinicopathologic significance of TRAP1 expression in colorectal cancer: a large scale study of human colorectal adenocarcinoma tissues. ( 28088229 )
2017
33
Aurora Kinase A Is a Prognostic Marker in Colorectal Adenocarcinoma. ( 28013532 )
2017
34
Late recurrence of colorectal adenocarcinoma as a renal tumour by direct spread via the ureter. ( 28588649 )
2017
35
Detection of Mismatch Repair Deficiency and Microsatellite Instability in Colorectal Adenocarcinoma by Targeted Next-Generation Sequencing. ( 27863258 )
2017
36
An Unusual Case of Colorectal Adenocarcinoma Presenting as an Anterior Mediastinal Mass. ( 29169975 )
2017
37
miR-15a-5p, A Novel Prognostic Biomarker, Predicting Recurrent Colorectal Adenocarcinoma. ( 28405803 )
2017
38
Doxorubicin-Wrapped Zinc Oxide Nanoclusters for the Therapy of Colorectal Adenocarcinoma. ( 29143771 )
2017
39
KRAS and PIK3CA mutations in colorectal adenocarcinomas correlate with aggressive histological features and behavior. ( 28188750 )
2017
40
Two case reports: Colorectal adenocarcinoma in children. ( 29145239 )
2017
41
Eukaryotic translation initiation factor 4E (eIF-4E) expressions are associated with poor prognosis in colorectal adenocarcinoma. ( 28242042 )
2017
42
FGFR2 Amplification in Colorectal Adenocarcinoma. ( 28835367 )
2017
43
Pleomorphic adenoma gene like-2 induces epithelial-mesenchymal transition via Wnt/I^-catenin signaling pathway in human colorectal adenocarcinoma. ( 28259923 )
2017
44
Evaluation of safety, feasibility and the long-term outcomes of colorectomy for colorectal adenocarcinoma in patients older than 80 years of age. ( 29046791 )
2017
45
Implications of inflammation and remodeling of the enteric glial cells in colorectal adenocarcinoma. ( 28730232 )
2017
46
Clinical and Histopathologic Features of Colorectal Adenocarcinoma in Crohn's Disease. ( 28654553 )
2017
47
6-shogaol induces autophagic cell death then triggered apoptosis in colorectal adenocarcinoma HT-29 cells. ( 28641163 )
2017
48
Hierarchical cluster analysis and chemical characterisation of Myrtus communis L. essential oil from Yemen region and its antimicrobial, antioxidant and anti-colorectal adenocarcinoma properties. ( 28068844 )
2017
49
Human epidermal growth factor (Her-2) in gastric and colorectal adenocarcinoma. ( 28770892 )
2017
50
Survival benefits in colorectal adenocarcinoma with the use of metformin among a black diabetic inner city population. ( 29308089 )
2017

Variations for Colorectal Adenocarcinoma

Expression for Colorectal Adenocarcinoma

Search GEO for disease gene expression data for Colorectal Adenocarcinoma.

Pathways for Colorectal Adenocarcinoma

Pathways related to Colorectal Adenocarcinoma according to GeneCards Suite gene sharing:

(show top 50) (show all 60)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.52 BRAF CDK8 CTNNB1 EGFR HRAS KRAS
2
Show member pathways
12.98 BRAF CDH1 CDX2 CTNNB1 HRAS KRAS
3 12.77 BRAF EGFR HRAS KRAS TP53
4
Show member pathways
12.77 BRAF CDH1 CTNNB1 EGFR HRAS KRAS
5
Show member pathways
12.74 BRAF CDH1 EGFR HRAS KRAS TP53
6
Show member pathways
12.69 BRAF CDH1 CTNNB1 EGFR HRAS KRAS
7
Show member pathways
12.68 BRAF EGFR HRAS KRAS TP53
8 12.68 BRAF CDH1 CTNNB1 EGFR HRAS KRAS
9
Show member pathways
12.67 BRAF CDH1 CTNNB1 HRAS KRAS TP53
10
Show member pathways
12.55 CTNNB1 EGFR HRAS KRAS MSH2 TP53
11 12.52 AURKA CDK8 MLH1 MSH2 TP53
12
Show member pathways
12.52 BRAF CDH1 CDX2 CTNNB1 EGFR HRAS
13
Show member pathways
12.51 BRAF EGFR HRAS KRAS TP53
14
Show member pathways
12.48 BRAF EGFR HRAS KRAS TP53
15
Show member pathways
12.46 BRAF CDH1 CTNNB1 EGFR HRAS KRAS
16 12.43 CTNNB1 HRAS KRAS TP53
17
Show member pathways
12.43 CTNNB1 EGFR HRAS KRAS
18
Show member pathways
12.43 CTNNB1 EGFR HRAS KRAS TP53
19
Show member pathways
12.4 BRAF CTNNB1 HRAS KRAS
20
Show member pathways
12.28 BRAF FGFBP1 HRAS KRAS
21
Show member pathways
12.28 BRAF CDH1 CTNNB1 HRAS
22 12.24 BRAF CTNNB1 EGFR HRAS KRAS TP53
23
Show member pathways
12.23 BRAF HRAS KRAS TP53
24
Show member pathways
12.19 BRAF HRAS KRAS TP53
25 12.16 EGFR HRAS KRAS TP53
26
Show member pathways
12.16 BRAF HRAS KRAS TP53
27 12.14 AURKA BRAF EGFR HRAS KRAS
28
Show member pathways
12.1 BRAF EGFR HRAS KRAS
29 12.08 EGFR MLH1 MSH2 TP53
30
Show member pathways
12.07 BRAF EGFR KRAS
31 12.03 CDH1 CTNNB1 HRAS KRAS
32 12.03 BRAF EGFR HRAS KRAS TP53
33 11.99 CTNNB1 HRAS KRAS TP53
34 11.98 CTNNB1 HRAS KRAS TP53
35 11.93 BRAF CTNNB1 EGFR HRAS KRAS TP53
36 11.84 EGFR HRAS KRAS
37
Show member pathways
11.81 BRAF HRAS KRAS
38 11.78 BRAF CDH1 CTNNB1 EGFR KRAS MLH1
39 11.75 MLH1 MSH2 TP53
40 11.74 CDH1 CTNNB1 EGFR
41 11.71 BRAF CDH1 EGFR HRAS KRAS TP53
42 11.69 HRAS KRAS TP53
43
Show member pathways
11.69 BRAF HRAS KRAS
44 11.66 EGFR HRAS KRAS TP53
45 11.65 BRAF HRAS KRAS
46 11.61 EGFR HRAS KRAS
47 11.54 EGFR HRAS KRAS
48
Show member pathways
11.45 MLH1 MSH2 TP53
49 11.44 CDH1 CTNNB1 EGFR
50 11.42 BRAF EGFR HRAS KRAS

GO Terms for Colorectal Adenocarcinoma

Cellular components related to Colorectal Adenocarcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 flotillin complex GO:0016600 8.62 CDH1 CTNNB1

Biological processes related to Colorectal Adenocarcinoma according to GeneCards Suite gene sharing:

(show all 22)
# Name GO ID Score Top Affiliating Genes
1 positive regulation of gene expression GO:0010628 9.92 BRAF CTNNB1 HRAS KRAS TP53
2 cell proliferation GO:0008283 9.91 CTNNB1 EGFR HRAS PIM2 TP53
3 positive regulation of transcription, DNA-templated GO:0045893 9.91 CDH1 CDX2 CTNNB1 EGFR PIM2 TP53
4 negative regulation of apoptotic process GO:0043066 9.88 AURKA BRAF CEACAM5 EGFR PIM2 TP53
5 Ras protein signal transduction GO:0007265 9.77 HRAS KRAS TP53
6 cellular response to drug GO:0035690 9.75 BRAF EGFR TP53
7 positive regulation of MAP kinase activity GO:0043406 9.73 EGFR HRAS KRAS
8 positive regulation of cell proliferation GO:0008284 9.73 CDX2 CTNNB1 EGFR FGFBP1 HRAS KRAS
9 epidermal growth factor receptor signaling pathway GO:0007173 9.72 EGFR HRAS KRAS
10 negative regulation of neuron apoptotic process GO:0043524 9.67 BRAF HRAS KRAS MSH2
11 determination of adult lifespan GO:0008340 9.61 MSH2 TP53
12 entry of bacterium into host cell GO:0035635 9.6 CDH1 CTNNB1
13 positive regulation of isotype switching to IgG isotypes GO:0048304 9.58 MLH1 MSH2
14 positive regulation of fibroblast growth factor receptor signaling pathway GO:0045743 9.57 CTNNB1 FGFBP1
15 response to isolation stress GO:0035900 9.54 HRAS KRAS
16 ERBB2 signaling pathway GO:0038128 9.5 EGFR HRAS KRAS
17 cellular response to indole-3-methanol GO:0071681 9.49 CDH1 CTNNB1
18 positive regulation of isotype switching to IgA isotypes GO:0048298 9.48 MLH1 MSH2
19 somatic recombination of immunoglobulin gene segments GO:0016447 9.46 MLH1 MSH2
20 negative regulation of cell proliferation GO:0008285 9.43 CTNNB1 FABP6 FGFBP1 HRAS PIM2 TP53
21 somatic recombination of immunoglobulin genes involved in immune response GO:0002204 9.16 MLH1 MSH2
22 anterior/posterior axis specification GO:0009948 8.8 AURKA CDX2 CTNNB1

Molecular functions related to Colorectal Adenocarcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 protein heterodimerization activity GO:0046982 9.83 AURKA BRAF CTNNB1 EGFR TP53
2 protein kinase activity GO:0004672 9.8 AURKA BRAF CDK8 EGFR PIM2
3 ATP binding GO:0005524 9.76 AURKA BRAF CDK8 EGFR MLH1 MSH2
4 protein kinase binding GO:0019901 9.65 AURKA CTNNB1 EGFR MSH2 TP53
5 protein phosphatase binding GO:0019903 9.5 CTNNB1 EGFR TP53
6 mismatched DNA binding GO:0030983 9.37 MLH1 MSH2
7 nucleotide binding GO:0000166 9.1 AURKA BRAF EGFR HRAS KRAS PIM2
8 guanine/thymine mispair binding GO:0032137 8.96 MLH1 MSH2

Sources for Colorectal Adenocarcinoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....